JB Chemicals & Pharmaceuticals Ltd. (IN:JBCHEPHARM)
:JBCHEPHARM
Want to see IN:JBCHEPHARM full AI Analyst Report?
Top Page
JB Chemicals & Pharmaceuticals Ltd.
(JBCHEPHARM)
Select Model
Select Model
Rating:74Outperform
Price Target:
₹2,390.00
▲(29.34% Upside)
Action:Upgraded
Date:05/13/26
The score is driven primarily by strong financial performance—especially the conservative balance sheet and solid profitability—offset by a high valuation (elevated P/E and low yield). Technicals are supportive with price above key moving averages and positive MACD, though momentum indicators suggest the stock is approaching overbought levels.
Positive Factors
Conservative balance sheet
Very low leverage and a strengthening equity base provide durable financial flexibility. Near-negligible debt reduces interest risk, supports investment or acquisitions, and helps absorb industry cyclicality, improving long-term resilience and strategic optionality.
Negative Factors
Slowing revenue growth
A material deceleration to low-single-digit revenue growth weakens the growth runway and limits operating-leverage benefits. If persistent, slower top-line expansion will constrain earnings growth and the ability to scale margins without new product launches or geographic expansion.
Read all positive and negative factors
Positive Factors
Negative Factors
Conservative balance sheet
Very low leverage and a strengthening equity base provide durable financial flexibility. Near-negligible debt reduces interest risk, supports investment or acquisitions, and helps absorb industry cyclicality, improving long-term resilience and strategic optionality.
Read all positive factors
JB Chemicals & Pharmaceuticals Ltd. (JBCHEPHARM) vs. iShares MSCI India ETF (INDA)
Market Cap
₹346.86B
Dividend Yield0.86%
Average Volume (3M)2.67K
Price to Earnings (P/E)45.7
Beta (1Y)0.44
Revenue Growth5.87%
EPS Growth6.56%
CountryIN
Employees5,311
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)46.08
Shares Outstanding160,558,700
10 Day Avg. Volume4,569
30 Day Avg. Volume2,671
Financial Highlights & Ratios
PEG Ratio7.16
Price to Book (P/B)7.80
Price to Sales (P/S)7.82
P/FCF Ratio51.69
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)61.23
Revenue Forecast (FY)₹47.52B
JB Chemicals & Pharmaceuticals Ltd. Business Overview & Revenue Model
Company Description
J. B. Chemicals & Pharmaceuticals Limited manufactures and markets various pharmaceutical formulations, herbal remedies, and active pharmaceutical ingredients in India and internationally. Its principal products include Cilnidipine, Ranitidine, an...
How the Company Makes Money
JB Chemicals & Pharmaceuticals makes money primarily by selling pharmaceutical products, with revenue driven by (1) domestic India formulations and branded generic medicines sold through prescription and trade channels, and (2) international sales...
JB Chemicals & Pharmaceuticals Ltd. Financial Statement Overview
Summary
Income Statement
82
Very Positive
Balance Sheet
92
Very Positive
Cash Flow
78
Positive
| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 40.36B | 41.48B | 38.62B | 34.48B | 31.17B | 24.24B |
| Gross Profit | 26.81B | 18.96B | 25.22B | 22.45B | 19.32B | 15.81B |
| EBITDA | 11.43B | 11.07B | 10.69B | 9.33B | 7.05B | 5.83B |
| Net Income | 7.18B | 7.09B | 6.60B | 5.53B | 4.10B | 3.85B |
Balance Sheet | ||||||
| Total Assets | 47.12B | 49.69B | 42.74B | 39.94B | 35.54B | 26.07B |
| Cash, Cash Equivalents and Short-Term Investments | 9.01B | 8.85B | 4.50B | 4.60B | 2.69B | 566.50M |
| Total Debt | 409.10M | 36.00M | 278.90M | 3.78B | 5.72B | 545.59M |
| Total Liabilities | 9.07B | 8.09B | 8.40B | 10.71B | 10.74B | 4.69B |
| Stockholders Equity | 38.06B | 41.59B | 34.33B | 29.23B | 24.80B | 21.34B |
Cash Flow | ||||||
| Free Cash Flow | 3.16B | 6.27B | 8.05B | 5.39B | -1.39B | -5.37B |
| Operating Cash Flow | 3.62B | 7.11B | 9.02B | 8.01B | 6.26B | 1.70B |
| Investing Cash Flow | -2.98B | -5.96B | -2.96B | -4.08B | -9.62B | 23.20M |
| Financing Cash Flow | -863.90M | -1.20B | -5.80B | -3.41B | 3.57B | -1.38B |
JB Chemicals & Pharmaceuticals Ltd. Technical Analysis
Positive
1847.80
Price Trends
2066.11
Positive
1981.52
Positive
1849.49
Positive
Market Momentum
34.36
Negative
59.84
Neutral
51.29
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:JBCHEPHARM, the sentiment is Positive. The current price of 1847.8 is below the 20-day moving average (MA) of 2098.61, below the 50-day MA of 2066.11, and below the 200-day MA of 1849.49, indicating a bullish trend. The MACD of 34.36 indicates Negative momentum. The RSI at 59.84 is Neutral, neither overbought nor oversold. The STOCH value of 51.29 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:JBCHEPHARM.
JB Chemicals & Pharmaceuticals Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
79 Outperform | ₹398.61B | 33.18 | ― | 1.04% | 17.31% | 14.93% | |
74 Outperform | ₹346.86B | 45.71 | ― | 0.86% | 5.87% | 6.56% | |
73 Outperform | ₹417.59B | 27.58 | ― | 0.28% | 8.92% | 24.73% | |
70 Outperform | ₹202.20B | 51.42 | ― | 0.47% | 12.37% | 30.97% | |
66 Neutral | ₹328.46B | 32.72 | ― | 0.21% | 16.56% | 34.08% | |
54 Neutral | ₹261.81B | 28.73 | ― | ― | 11.99% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
IN:JBCHEPHARM
JB Chemicals & Pharmaceuticals Ltd.
2,160.35
507.03
30.67%
IN:AJANTPHARM
Ajanta Pharma Limited
3,190.50
580.95
22.26%
IN:EMCURE
Emcure Pharmaceuticals Limited
1,732.50
661.17
61.71%
IN:ERIS
Eris Lifesciences Ltd
1,459.50
-45.35
-3.01%
IN:IPCALAB
IPCA Laboratories Limited
1,646.25
177.84
12.11%
IN:WOCKPHARMA
Wockhardt Limited
1,611.30
270.90
20.21%
JB Chemicals & Pharmaceuticals Ltd. Corporate Events
JB Chemicals & Pharmaceuticals Sets Investor Call to Discuss Q4 FY26 Results
May 7, 2026
JB Chemicals Pharmaceuticals has scheduled an investors and analysts conference call with its management on May 12, 2026, at 8:30 a.m. IST to discuss financial results and business developments for the fourth quarter ended March 31, 2026. The cal...
JB Chemicals Shareholders Clear Key Scheme Resolution at Court-Convened Meeting
Apr 28, 2026
JB Chemicals Pharmaceuticals Ltd. has reported that its equity shareholders approved a proposed corporate Scheme at a court-convened general meeting held via video conferencing on April 28, 2026. The resolution received the required majority in n...
JB Chemicals Shareholders Approve Amalgamation with Torrent Pharma at NCLT Meeting
Apr 28, 2026
JB Chemicals Pharmaceuticals Ltd. informed the stock exchange that it held a National Company Law Tribunal (NCLT) convened meeting of its equity shareholders on April 28, 2026 via video conferencing. The meeting was properly constituted with the ...
JB Chemicals Publishes NCLT-Directed Notice for Equity Shareholders’ Meeting
Mar 28, 2026
JB Chemicals Pharmaceuticals Ltd. has notified the stock exchange that it has published a newspaper advertisement giving notice of a meeting of its equity shareholders. The shareholder meeting has been convened pursuant to an order dated March 23...
JB Chemicals & Pharmaceuticals Publishes Postal Ballot Notices for Shareholders
Feb 23, 2026
JB Chemicals Pharmaceuticals has notified the stock exchange that it has published newspaper advertisements related to a postal ballot process for its shareholders. The notices, carried in the English and Gujarati editions of the Financial Expres...
JB Chemicals seeks shareholder nod for board overhaul via e-voting
Feb 20, 2026
JB Chemicals Pharmaceuticals has launched a postal ballot process seeking shareholder approval for several board appointments, including elevating Aman Mehta to director and managing director. The exercise also covers the induction of Amal Kelshi...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.